Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS Buys Into Promising Neuropathic Pain Market Via Allergan Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

New compound could one day help Bristol tap into a growing area of unmet need in diabetes.

You may also be interested in...



Is BMS/AstraZeneca's Dapagliflozin More Than Just Another Oral Diabetes Drug?

Phase III results with metformin leave some disappointed, while another study hints of niche role in insulin-resistant patients.

AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared

AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.

Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

Bristol-Myers Squibb is buying the biotech company Medarex in a deal valued at $2.4 billion, or $16.00 per share in cash, the companies announced July 22. In doing so, Bristol gains full rights to the late-stage cancer drug ipilimumab and to innovative technologies for developing immunology and oncology humanized antibodies

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel